Unity Biotechnology, Inc. (NASDAQ:UBX) Expected to Announce Earnings of -$0.29 Per Share

Wall Street analysts forecast that Unity Biotechnology, Inc. (NASDAQ:UBXGet Rating) will report earnings per share (EPS) of ($0.29) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Unity Biotechnology’s earnings. Unity Biotechnology reported earnings per share of ($0.32) in the same quarter last year, which suggests a positive year over year growth rate of 9.4%. The business is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Unity Biotechnology will report full year earnings of ($1.20) per share for the current fiscal year, with EPS estimates ranging from ($1.34) to ($1.07). For the next financial year, analysts anticipate that the business will post earnings of ($1.55) per share, with EPS estimates ranging from ($1.64) to ($1.46). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Unity Biotechnology.

Unity Biotechnology (NASDAQ:UBXGet Rating) last released its earnings results on Tuesday, May 10th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Separately, Zacks Investment Research upgraded Unity Biotechnology from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Saturday, March 19th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Unity Biotechnology presently has an average rating of “Buy” and a consensus target price of $5.71.

Several large investors have recently made changes to their positions in UBX. FMR LLC lifted its position in shares of Unity Biotechnology by 18.2% in the first quarter. FMR LLC now owns 4,551,523 shares of the company’s stock worth $36,913,000 after buying an additional 700,500 shares during the last quarter. Morgan Stanley lifted its position in shares of Unity Biotechnology by 445.2% in the second quarter. Morgan Stanley now owns 914,566 shares of the company’s stock worth $4,244,000 after buying an additional 746,825 shares during the last quarter. BlackRock Inc. increased its stake in shares of Unity Biotechnology by 2.0% in the third quarter. BlackRock Inc. now owns 900,630 shares of the company’s stock worth $2,701,000 after purchasing an additional 18,059 shares during the period. Geode Capital Management LLC lifted its position in shares of Unity Biotechnology by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 318,673 shares of the company’s stock worth $956,000 after purchasing an additional 12,428 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Unity Biotechnology by 25.0% during the 3rd quarter. Renaissance Technologies LLC now owns 640,700 shares of the company’s stock worth $1,922,000 after purchasing an additional 128,100 shares during the last quarter. 21.22% of the stock is owned by institutional investors.

NASDAQ UBX traded up $0.07 during mid-day trading on Monday, reaching $0.81. 287,837 shares of the company’s stock traded hands, compared to its average volume of 344,185. Unity Biotechnology has a 1-year low of $0.70 and a 1-year high of $5.09. The company has a fifty day simple moving average of $1.01 and a 200-day simple moving average of $1.41. The company has a market cap of $56.01 million, a price-to-earnings ratio of -0.75 and a beta of 0.39.

About Unity Biotechnology (Get Rating)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

Further Reading

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unity Biotechnology (NASDAQ:UBX)

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.